Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Open Access
- 11 April 2016
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 34 (7) , 709-721
Abstract
In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain and relapse. We conducted a cost-utility analysis of lurasidone versus aripiprazole from the perspective of healthcare services, using Scotland and Wales as specific case studies.Keywords
This publication has 39 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority studySchizophrenia Research, 2013
- Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other AntipsychoticsThe Journal of Clinical Psychiatry, 2013
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled studyPsychopharmacology, 2012
- Cardiovascular Disease Mortality in Patients With Chronic Schizophrenia Treated With ClozapineThe Journal of Clinical Psychiatry, 2010
- Lurasidone in the Treatment of Acute SchizophreniaThe Journal of Clinical Psychiatry, 2009
- Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitationHealth and Quality of Life Outcomes, 2008
- SchizophreniaBMJ, 2007
- Heart Disease, Schizophrenia, and Affective Psychoses: Epidemiology of Risk in Primary CareCommunity Mental Health Journal, 2005
- CME ArticleThe Primary Care Companion For CNS Disorders, 2005